VEGF inhibitors: a new era in the treatment of metastatic ovarian cancer
O affect angiogenesis is one of the key goals of therapy for ovarian cancer (OC). The advent of targeted drugs that selectively affect neoangiogenesis has been a breakthrough in treating OC in the past decade. By now the only drug validly demonstrating antiangiogenic activity is bevacizumab whose ef...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2013-06-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/26901 |